Hyperion DeFi, Inc. is the first U.S. publicly listed company building a long-term strategic treasury of HYPE. The Company provides investors with streamlined access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility. Hyperion DeFi is also developing its proprietary Optejet User Filled Device that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers.
| Revenue (Most Recent Fiscal Year) | $0.81M |
| Net Income (Most Recent Fiscal Year) | $-45.31M |
| PE Ratio (Current Year Earnings Estimate) | 1.76 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 34.83 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.47 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 474.88% |
| Net Margin (Trailing 12 Months) | 416.56% |
| Return on Equity (Trailing 12 Months) | -11.62% |
| Return on Assets (Trailing 12 Months) | -9.96% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.34 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.97 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.06 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.92 |
| Earnings per Share (Most Recent Fiscal Year) | $-9.40 |
| Diluted Earnings per Share (Trailing 12 Months) | $-6.53 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 15.54M |
| Free Float | 14.37M |
| Market Capitalization | $48.79M |
| Average Volume (Last 20 Days) | 0.35M |
| Beta (Past 60 Months) | 2.53 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 25.84% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |